GLAXOSMITHKLINE

The emergence of drug-resistant or superbug strains of gonorrhoea is caused by unregulated access to and overuse of antibiotics, which helps fuel natural genetic mutations within the bacteria.

GlaxoSmithKline Plc (NYSE: GSK) will begin a $2.6 billion hostile takeover bid for Human Genome Sciences (NASDAQ: HGSI), the company announced Wednesday.

Stock index futures pointed to a lower open on Wall Street on Wednesday, with futures for the S&P 500 down 0.6 percent, Dow Jones futures 0.3 percent weaker, and Nasdaq 100 futures off 0.5 percent at 04:54 a.m. EDT (0854 GMT).

When Odei Antwi-Agyei had the chance of introducing vaccines to prevent Ghana's children dying of diarrhea, or vaccines to stop them dying of pneumonia, he did what no African immunization chief has done before. He said he'd do both at the same time.

AstraZeneca has agreed to buy U.S. company Ardea Biosciences for $1.26 billion, giving it a new gout drug to bolster its weak pipeline in a deal that feeds a wave of M&A in the biotechnology sector.

Human Genome Sciences Inc has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline Plc, marking a new takeover battle in a drugs sector that has been swept by M&A recently.

The pharmaceutical industry is paying close attention to a case that could determine if about 90,000 sales representatives are entitled to overtime pay.

The top after-market NASDAQ gainers Friday were: Cornerstone OnDemand, TASER International, MAP Pharmaceuticals, Affymax, Avis Budget Group and Steel Dynamics. The top after-market NASDAQ losers were: Pacific Biosciences of California, Targacept, Ancestry.com, Theravance, Vocus and Commercial Vehicle Group.

Britain's largest drugmaker GlaxoSmithKline announced on Thursday plans to invest £500 million ($792 million) in local manufacturing operations, opening a facility in Scotland that is expected to create 1,000 jobs over the coming years.

Many patients taking a widely prescribed class of oral cancer drugs are also using a variety of medications that could reduce the effectiveness of the cancer treatment or increase its toxic side effects, according to research by Medco Health Solutions Inc.

Europe is undermining drug innovation by cutting prices, raising barriers to new medicines and freeloading off others in Asia and the United States who are more willing to pay, the boss of Pfizer, the world's largest drugmaker, said.

A research group is proposing a new tool in the fight against drug-resistant bacteria: turn infections into a rare disease.

Daiichi Sankyo Co. and GlaxoSmithKline have stated that they have agreed to form a 50-50 joint venture which will bring new products to the Japanese market.

Experimental obesity drug Qnexa won the backing of U.S. health advisors on Wednesday, raising hopes for approval of the first prescription weight-loss pill in 13 years.

Experimental obesity drug Qnexa won the backing of U.S. health advisors on Wednesday, raising hopes for approval of the first prescription weight-loss pill in 13 years.

The weightloss drugs like GlaxoSmithKline's Alli and Roche's Xenical run the risk of very rare liver-related side effects, according to European Medicines Agency.

Weakness in banks and commodity stocks dragged Britain's leading share index lower on Monday as the protracted search for a Greek bond deal and concerns about economic growth kept investors nervous.

The world's major pharmaceutical companies joined forces with governments and leading global health organizations Monday to donate drugs and scientific know-how to help control or wipe out 10 neglected tropical diseases by 2020.

Whistle-blowers earned more than $532 million in 2011 through lawsuits alleging fraud against the U.S. government, a record for such payouts, according to a law-firm study published on Friday.

European stocks edged up in thin pre-holiday trade on Tuesday at mid-day, boosted by a successful Spanish debt auction and a sharp rise in German business sentiment, though strategists said the continuing euro zone debt crisis would limit any gains.

The U.S. Supreme Court will review an overtime pay case from a nationwide class of GlaxoSmithKline pharmaceutical sales representatives.